JANX Company Profile and Key Details
Janux Therapeutics, Inc.
JANX Stock Price Chart
Stock Price Today
Janux Therapeutics, Inc. (JANX) stock declined over -1.78%, trading at $40.18 on NASDAQ, down from the previous close of $40.91. The stock opened at $40.85, fluctuating between $39.33 and $41.35 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Company Information
| Employees | 76 |
| Beta | 3.52 |
| Sales or Revenue | $8.08M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Janux Therapeutics, Inc. (NASDAQ: JANX) stock price is $40.18 in the last trading session. During the trading session, JANX stock reached the peak price of $41.35 while $39.33 was the lowest point it dropped to. The percentage change in JANX stock occurred in the recent session was -1.78% while the dollar amount for the price change in JANX stock was -$0.73.
The NASDAQ listed JANX is part of Biotechnology industry that operates in the broader Healthcare sector. Janux Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Brenda Van Vreeswyk
Head of HR
Mr. Tighe M. Reardon C.F.A., C.P.A., CPA
Acting Chief Financial Officer
Dr. David Alan Campbell Ph.D.
Pres, Chief Executive Officer & Director
Dr. Wayne Godfrey M.D.
Chief Medical Officer
Mr. Tommy Diraimondo Ph.D.
Senior Director of Research
Mr. Tighe M. Reardon C.F.A., CPA, CPA
Acting Chief Financial Officer
Mr. James Pennington
Gen. Counsel
Mr. Charles M. Winter
Senior Vice President of Chemistry, Manufacturing & Controls
Mr. Andy Hollman Meyer
Chief Bus. Officer
Mr. Byron Robinson J.D., Ph.D.
Chief Strategy Officer
JANX's closing price is 415.79% higher than its 52-week low of $7.79 where as its distance from 52-week high of $71.71 is -43.97%.
Number of JANX employees currently stands at 76.
Official Website of JANX is: https://www.januxrx.com
JANX could be contacted at phone 858 750 4700 and can also be accessed through its website. JANX operates from 11099 North Torrey Pines Road, La Jolla, CA 92037, United States.
JANX stock volume for the day was 1.39M shares. The average number of JANX shares traded daily for last 3 months was 1.11M.
The market value of JANX currently stands at $2.32B with its latest stock price at $40.18 and 57.8M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com